In this trial involving adult patients undergoing cardiac surgery with cardiopulmonary bypass, 20% albumin fluid bolus therapy (FBT) compared to crystalloid FBT did not decrease the occurrence of acute kidney injury (AKI).

However, in patients who developed more severe AKI, those assigned 20% albumin had an attenuated duration and severity of AKI (expressed as time weighted creatinine) compared to those receiving crystalloid FBT strategy.

This information can be used by clinicians to guide their choice of therapy in patients with an elevated risk of AKI or those who are developing stage 2 & 3 AKI.

We included 452 patients in the modified intention-to-treat population (224 in the 20% albumin group and 228 in the crystalloid group). AKI occurred in 54 (24%) patients in the 20% albumin group and 50 (22%) in the crystalloid group (odds ratio, 1.13; 95% confidence interval [CI], 0.73 to 1.76).

Read More